Improvement in either weight or HbA1c – but never both

Numerous studies show that glucagon-like peptide-1 receptor agonists (GLP1-RA) can significantly reduce the risk of diabetes-related complications and also reduce mortality. Despite their proven efficacy in trial designs, patient response to GLP1-RA therapy in the real world remains highly variable, particularly in terms of glycemic control and weight loss. The reasons for these variations and their relationship to specific patient characteristics are still unclear in clinical practice.